Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Posted on by Pencis

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Guangxi Medical University Cancer Hospital | China

Author Profile

Scopus

Orcid id

šŸŒŸ Distinguished Scientist Award: Dr. Chen Wang šŸŒŸ

Full Name: Chen Wang
Gender: Male
Designation: Associate Research Fellow
Department: Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer
Institution/Organization: Guangxi Medical University Cancer Hospital
Qualification: Ph.D.
Area of Specialization: Oncology Therapeutics and Novel Approaches
Sub Division: Anti-tumor Nanomaterials

šŸ“š Education and Experience

Born in Liaoning, China, in 1988, Dr. Chen Wang has dedicated his career to advancing cancer treatment through innovative research in materials science and engineering. He earned his BS (2010) and MS (2013) degrees from Shenyang University of Technology, followed by a Ph.D. from Harbin Engineering University in 2019. Dr. Wang’s postdoctoral research took place at the Changchun Institute of Applied Chemistry and Southern Medical University. He began his academic career at Jilin University of Chemical Technology and joined Guangxi Medical University Cancer Hospital in 2020, becoming an associate research fellow in 2022.

šŸ§¬ Research and Innovations

Dr. Wang specializes in the synthesis and clinical application of novel anti-tumor nanomaterials. His pioneering work on calcium overload as a novel treatment for tumor cells has garnered significant attention. The development of GMCP (GOx@MMPB@CaP-PEG) nanoparticles showcases his innovative approach, combining enhanced intratumor reactive oxygen species (ROS) levels with photothermal therapy to promote apoptosis in tumor cells.

šŸ† Achievements

  • Publications: Nearly 30 SCI-indexed original articles, including 11 as first/corresponding author.
  • Projects: Completed 12 research projects, with 5 as the principal investigator.
  • Patents: Holds 7 patents.
  • Editorial Roles: Serves on the editorial boards and as a reviewer for multiple journals.
  • Memberships: Member of the China Food and Drug Enterprise Quality and Safety Promotion Association.
  • Citations: 495 citations in Scopus/Web of Science.
  • H-index: 13.
  • Impact Factor: Cumulative impact factor of 141.8 over the last three years.

Dr. Wang’s work in oncology therapeutics, particularly in anti-tumor nanomaterials, positions him as a leading figure in his field, making him a deserving recipient of the Distinguished Scientist Award.

šŸŒ Professional Links

šŸ“„ Certifications

  • Education Proof (Ph.D.): 1021722019110003
  • Government ID (Passport): E36369406

Dr. Chen Wang’s dedication to research, innovation, and the application of novel cancer treatments underscores his significant contributions to the field of oncology therapeutics.

 

šŸ“ŠšŸ”¬Notable Publication:

 

 

 

 

Prof Dr. Rommel MarioRodriguez Burbano – Oncology and Precision Medicine – Best Researcher Award

Posted on by Pencis

Prof Dr. Rommel MarioRodriguez Burbano - Oncology and Precision Medicine - Best Researcher Award

Ophir Loyola Hospital - Brazil

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Rommel Mario RodrĆ­guez Burbano began his academic journey by earning a degree in Biomedicine from the Federal University of ParĆ” in 1989. He then pursued further education, completing his Master's (1993) and Ph.D. (1998) in Biological Sciences (Genetics) from the Faculty of Medicine of RibeirĆ£o Preto, University of SĆ£o Paulo.

PROFESSIONAL ENDEAVORS

After completing his formal education, Rommel embarked on a diverse and impactful professional career. He conducted post-doctoral research in Morphology at the Discipline of Genetics, Escola Paulista de Medicina, Federal University of SĆ£o Paulo in 2005. Currently, he holds the prestigious position of Full Professor at the Federal University of ParĆ”.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Rommel Mario RodrĆ­guez Burbano's contributions to academia are significant and multifaceted. His research primarily focuses on Human Genetics, Cell Biology, and Oncology. Throughout his career, he has demonstrated a keen interest in understanding molecular mechanisms underlying diseases, particularly cancer.

IMPACT AND INFLUENCE

Rommel's work has had a profound impact on the scientific community. His extensive publication record, comprising 296 scientific articles in specialized journals, one book, and seven book chapters, reflects his dedication to advancing knowledge in his field.

ACADEMIC CITATIONS

Rommel's research output has garnered considerable attention, as evidenced by his numerous academic citations. His work is widely recognized and cited by peers, contributing significantly to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS

As a mentor and supervisor, Rommel has played a pivotal role in shaping the next generation of scientists. He has supervised a total of 44 master's theses, 41 doctoral theses, and mentored five postdoctoral fellows. His legacy extends beyond his own research contributions, influencing the work of numerous scholars who have benefited from his guidance and expertise.

HIGHLIGHTS

Rommel currently serves as the Coordinator of the Molecular Biology Laboratory at Hospital Ophir Loyola in BelƩm, ParƔ, indicating his leadership in translational research.He holds the Process and Molecular Biomarker patent, demonstrating his innovative approach to addressing scientific challenges.Rommel's involvement in editorial boards of 12 scientific journals and his role as a reviewer for numerous scientific publications underscore his commitment to peer-reviewed research and quality scholarship.

NOTABLE PUBLICATIONS

Homocystein, Vitamin B12 and Folic Acid as Screening Biomarkers in Early Diagnosis and Gastric Cancer Monitoring.Ā  2024

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials. 2024

Molecular Profile of Variants Potentially Associated with Severe Forms of COVID-19 in Amazonian Indigenous Populations. 2024 (1)

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. 2024

PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia. 2023

 

 

Dr. Takashi Takeshita – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Dr. Takashi Takeshita - Cancer Genetics - Best Researcher Award

Kumamoto City Hospital - Japan

Author Profile

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Takashi Takeshita initiated his academic journey by obtaining a Medical Doctorate (M.D.) from the National Defense Medical College, Saitama, Japan, in 2005. He furthered his education by earning a Ph.D. from St. Marianna University School of Medicine, Kanagawa, Japan, in 2012. These early academic pursuits established the foundation for his future contributions to cancer genetics.

PROFESSIONAL ENDEAVORS

Since 2022, Takashi Takeshita has been serving as the Chief of Breast and Endocrine Surgery at Kumamoto City Hospital, Japan. His professional journey is marked by significant achievements, including the receipt of several prestigious awards: the 2017 Research Award from the Japanese Breast Cancer Society, the 2017 Research Award from the Japanese Society of Medical Oncology, the 2018 Young Investigatorā€™s Award from the Japan Surgical Society, and the 2018 Excellent Presentation Award from the Japanese Breast Cancer Society.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICSĀ 

Takashi Takeshita's 19-year research career spans various research institutes, showcasing a robust expertise in cancer genetics. His focus includes genetic analysis of clinical specimens, utilizing techniques such as digital PCR for tumor tissue and plasma DNA, immunohistochemical staining, automated assay robot operation, and more. His experience in large-scale cell culture and comprehensive knowledge of molecular biology, pharmacology, and analytical methods underscore his dedication to advancing cancer research.

IMPACT AND INFLUENCE

The awards received by Takashi Takeshita, coupled with his role as the Chief of Breast and Endocrine Surgery, affirm his impact and influence in the medical field. His leadership and contributions to cancer genetics, particularly in breast cancer research, position him as a prominent figure. His membership in esteemed academic societies, including the Japanese Breast Cancer Society, Japan Surgical Society, Japanese Cancer Association, Japanese Society of Medical Oncology, and the American Association for Cancer Research, further reflects his influence on a global scale.

ACADEMIC CITES

Takashi Takeshita's involvement in renowned academic societies and receipt of research awards suggest that his work likely receives recognition and citations within the scientific community. His expertise in genetic analysis and clinical research contributes to the advancement of cancer genetics literature.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Takashi Takeshita's legacy is built upon a foundation of excellence in cancer genetics, marked by numerous awards and leadership roles. His dedication to advancing breast and endocrine surgery and his contributions to genetic analysis techniques set the stage for a lasting impact. Looking ahead, Takeshita is poised to continue making significant contributions to cancer genetics, shaping the future landscape of research in breast cancer and beyond. His membership in international societies signifies a commitment to global collaboration and further advancements in cancer research.

NOTABLE PUBLICATIONS

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. 2024

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment. 2023

Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer.Ā 2023 (5)

Fulvestrant plus palbociclib in advanced or metastatic hormone.Ā 2023 (2)

High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment. 2023

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcomeā€“ A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023

 

Personalized Cancer Treatment

Posted on by Pencis

Introduction: Personalized cancer treatment represents a paradigm shift in oncology, moving away from one-size-fits-all approaches and towards tailoring treatments based on an individual’s unique genetic, molecular, and clinical characteristics. This approach holds the promise of maximizing treatment efficacy while minimizing side effects, offering new hope for cancer patients.

Subtopics in Personalized Cancer Treatment:

Genomic Profiling: Genomic analysis of a patient’s tumor can identify specific genetic mutations and alterations that drive cancer growth. Targeted therapies are then designed to attack these specific molecular vulnerabilities, leading to more effective treatment.

Immunotherapy and Immune Profiling: Personalized cancer treatment extends to immunotherapy, where the patient’s immune system is harnessed to fight cancer. Immune profiling helps identify immune checkpoints and tumor-specific antigens, aiding in the selection of suitable immunotherapies.

Biomarker-Based Therapy: Biomarkers such as hormone receptors, HER2 status, and PD-L1 expression guide treatment decisions in breast, lung, and other cancers. Personalization ensures that patients receive therapies tailored to their tumor’s unique characteristics.

Treatment Resistance Mitigation: Personalized approaches are essential in combating treatment resistance. Continuous monitoring and adaptation of treatment regimens based on evolving tumor profiles can help overcome resistance and extend the duration of response.

Clinical Trial Matching: Personalized treatment extends to the realm of clinical trials, where patients are matched with experimental therapies that align with their tumor’s genetic makeup. This accelerates drug development and provides patients with access to cutting-edge treatments.

These subtopics highlight the transformative potential of personalized cancer treatment, emphasizing its role in optimizing patient outcomes, minimizing adverse effects, and advancing the field of oncology towards precision medicine.